News Daily News SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide Michael O'Riordan December 18, 2025
News Daily News Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION Todd Neale December 16, 2025
News Daily News Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension Todd Neale October 07, 2025
News Conference News ESC 2025 Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF Michael O'Riordan August 29, 2025
News Daily News PREVENT Equations in BP Guidelines Means Better Treatment, the ACC/AHA Say Yael L. Maxwell August 28, 2025
News Daily News Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC Yael L. Maxwell August 18, 2025
News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Daily News POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies L.A. McKeown July 15, 2025
News Daily News Baxdrostat Shows Promise in Uncontrolled or Resistant Hypertension L.A. McKeown July 14, 2025
News Daily News CV Risk Modest for Most Cancer Survivors in Large Danish Registry L.A. McKeown June 17, 2025
News Daily News Majority of US Adults Have High Long-term Risk of CVD: NHANES Michael O'Riordan June 13, 2025
News Daily News Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding L.A. McKeown May 16, 2025
News Conference News European Congress on Obesity 2025 Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery Michael O'Riordan May 14, 2025
News Conference News SCAI 2025 When Early Cardiogenic Shock Isn’t Dealt With, Outcomes Can Suffer L.A. McKeown May 09, 2025
News Daily News Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds Michael O'Riordan April 25, 2025
News Daily News High-Sensitivity Troponin Tests Might Aid in Primary Prevention Yael L. Maxwell April 16, 2025
News Conference News ACC 2025 Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP Michael O'Riordan April 01, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
Presentation ACC 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial Presenter: Darren K. McGuire March 29, 2025
News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025